Table 2

Baseline histologic characteristics and stomach index score of enrolled subjects who completed the study by trial arma

CharacteristicPlacebo (n = 126)Treatment (n = 122)P
Gastritis, n (%)
 None01 (0.8)0.03
 Chronic14 (11.1)4 (3.3)
 Acute112 (88.9)117 (95.9)
Atrophy, n (%)
 None47 (37.3)56 (45.9)0.22
 Mild39 (31.0)28 (23.0)
 Moderate36 (28.6)30 (24.6)
 Severe4 (3.2)8 (6.6)
IM,c n (%)
 None60 (48.0)61 (50.0)0.08
 Mild18 (14.4)26 (21.3)
 Moderate17 (13.6)6 (4.9)
 Severe30 (24.0)29 (23.8)
Dysplasia, n (%)
 None106 (84.1)112 (91.8)0.14
 Mild18 (14.3)8 (6.6)
 Moderate2 (1.6)2 (1.6)
 Severe00
Worst biopsy diagnosis,d n (%)
 Normal01 (0.8)0.83
 Gastritis51 (40.5)46 (37.7)
 Atrophye10 (7.9)14 (11.5)
 IM63 (50.0)59 (48.4)
 Dysplasiae2 (1.6)2 (1.6)
Stomach index score,f n (%)
 Median0.500.500.93
 25%–75%0–2.00–1.9
 Range0–13.70–15.3
  • a Enrolled subjects who withdrew were not different at baseline from those who completed the study.

  • b χ2 test, Fisher’s exact test or median test, as appropriate.

  • c IM, intestinal metaplasia.

  • d Normal < chronic/active gastritis < moderate/severe atrophy < mild/moderate/severe IM < moderate dysplasia.

  • e To prevent misclassification, worst diagnoses of mild atrophy were grouped with gastritis because all of these subjects had underlying inflammation. Worst diagnoses of mild dysplasia were grouped with the next worst condition for each subject.

  • f Average score across both pathologists.